Cynthia Davenport
Pharmaceutical Regulatory Toxicology Consultant, Drug Safety Evaluation @Tigertox
Signup · Get unlimited contacts
WORK HISTORY
Pharmaceutical Regulatory Toxicology Consultant, Drug Safety Evaluation @Tigertox
President, PrincipalGeneral Toxicology • Neurotoxicology • Nonclinical / Preclinical Drug Safety • IND Enabling Studies • Nonclinical Drug Safety Development Strategies • Team Involvement/Leadership • Project Management • CRO Selection • Protocol Design, Study Placement, and Monitoring • Data Analyses • Report Writing and/or Review • Integrated Nonclinical Drug Safety Summary Document Preparation • Investigator Brochures • Regulatory Toxicology / Nonclinical Drug Safety Dossier Preparation • Impurity/Metabolite Qualification • Scientific Literature Reviews • Expert Report/ White Paper Preparation • Manuscript Preparation • Due-diligence • Academic Liaison • Peer Review
EDUCATION
Millsaps College
Bachelor of Science, Biology
University of California, Los Angeles - School of Medicine
Ph.D., Experimental Pathology
Chemical Industry Institute of Toxicology (CIIT; The Hamner Institute)
Post Doctoral, Toxicology
Stanford University School of Medicine
Post Doctoral, Neurology
Louisiana State University, Baton Rouge
Masters of Science, Physiology
SKILLS
ABOUT CYNTHIA DAVENPORT
Connect with me at: c••••••••@tigertox.com CEO, CSO, Recruiters, HR Managers, Hiring Managers connect with me to gain access to my network deep in industry Davenport, Ph.D. is a regulatory toxicology consultant with over 28 years of drug development expertise. Her consulting firm, TigerTox, specializes in the regulatory toxicology (nonclinical) of small-molecule drugs (human and veterinary) in multiple therapeutic areas.TigerTox facilitates moving client drugs from candidate nomination through IND/NDA.Over the past 28 years, Dr. Davenport has supplied documents / addressed queries for multiple filings (CTD, IB, IND, NDA, Product Label, MAA, NADA, MRL, ETP, and ATC), including 5 marketed products: DRAXXIN®, CONVENIA®, CERENIA®, GEODON®/ ZELDOX®, and ADVOCIN®. Cynthia has edited 30+ IBs and has contributed to the SUTENT® NDA. Dr. Davenport has supported numerous other Phase I, II, and global clinical trials. Notably, her specialization also includes CNS drugs (25+ new molecular entities). TigerTox tends to work best for companies who:• Need strategic planning / assessment of nonclinical toxicology package• Are ready to initiate their nonclinical toxicology (GLP/nonGLP) plans / studies• Need toxicology expertise during due diligence activities for in-licensed products• Desire preparation of a nonclinical safety regulatory dossier• Need experienced personnel for special projects and ongoing activitiesTigerTox ensures that the money / time allocated to drug development is strategically spent on an optimized preclinical drug safety package that supports all stages of the proposed clinical plan. We do it Right the First Time by ensuring that all studies are performed correctly and expediently, with the right documentation and oversight, and in a cost-effective manner.If you would like to brainstorm or collaborate on any of these perspectives, call me at +17•••••••75.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.